Rafael Cobas Paz-rekin lankidetzan egindako argitalpenak (6)

2022

  1. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

2021

  1. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets

    The Lancet, Vol. 397, Núm. 10270, pp. 199-207

2020

  1. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction

    Revista espanola de cardiologia (English ed.), Vol. 73, Núm. 2, pp. 114-122

  2. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

  3. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects

    European heart journal. Cardiovascular pharmacotherapy, Vol. 6, Núm. 1, pp. 31-42

2018

  1. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score

    International Journal of Cardiology, Vol. 254, pp. 10-15